BIOCON Stock Overview
Engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Biocon Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹335.95 |
| 52 Week High | ₹395.80 |
| 52 Week Low | ₹244.55 |
| Beta | 0.43 |
| 1 Month Change | 3.98% |
| 3 Month Change | -8.05% |
| 1 Year Change | 36.40% |
| 3 Year Change | -5.22% |
| 5 Year Change | 14.89% |
| Change since IPO | 732.85% |
Recent News & Updates
Here's What Analysts Are Forecasting For Biocon Limited (NSE:BIOCON) After Its Second-Quarter Results
Nov 02
Why Investors Shouldn't Be Surprised By Biocon Limited's (NSE:BIOCON) Low P/E
Nov 01Recent updates
Here's What Analysts Are Forecasting For Biocon Limited (NSE:BIOCON) After Its Second-Quarter Results
Nov 02Why Investors Shouldn't Be Surprised By Biocon Limited's (NSE:BIOCON) Low P/E
Nov 01Do Biocon's (NSE:BIOCON) Earnings Warrant Your Attention?
Oct 14These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively
Sep 20Biocon Limited's (NSE:BIOCON) Earnings Haven't Escaped The Attention Of Investors
Jun 29Is Biocon (NSE:BIOCON) A Risky Investment?
Jun 11Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50
Jun 11Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations
May 24Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50
May 23Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?
Mar 20Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next
Feb 12Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price
Jan 23Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price
Jan 03These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively
Nov 13Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)
Aug 03Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50
Jul 03Is Biocon (NSE:BIOCON) Using Too Much Debt?
Jul 02Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50
May 26Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)
Mar 28Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly
Feb 26Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate
Dec 17Is There An Opportunity With Biocon Limited's (NSE:BIOCON) 46% Undervaluation?
Sep 05Is Biocon (NSE:BIOCON) Using Too Much Debt?
Jul 13Shareholder Returns
| BIOCON | IN Biotechs | IN Market | |
|---|---|---|---|
| 7D | -4.8% | -4.6% | -4.2% |
| 1Y | 36.4% | 40.8% | 19.1% |
Return vs Industry: BIOCON underperformed the Indian Biotechs industry which returned 40.8% over the past year.
Return vs Market: BIOCON exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
| BIOCON volatility | |
|---|---|
| BIOCON Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: BIOCON has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: BIOCON's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 16,315 | Siddharth Mittal | www.biocon.com |
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab.
Biocon Limited Fundamentals Summary
| BIOCON fundamental statistics | |
|---|---|
| Market cap | ₹402.07b |
| Earnings (TTM) | ₹14.39b |
| Revenue (TTM) | ₹148.94b |
27.9x
P/E Ratio2.7x
P/S RatioIs BIOCON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOCON income statement (TTM) | |
|---|---|
| Revenue | ₹148.94b |
| Cost of Revenue | ₹56.11b |
| Gross Profit | ₹92.83b |
| Other Expenses | ₹78.44b |
| Earnings | ₹14.39b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 12.03 |
| Gross Margin | 62.33% |
| Net Profit Margin | 9.66% |
| Debt/Equity Ratio | 60.4% |
How did BIOCON perform over the long term?
See historical performance and comparisonDividends
0.1%
Current Dividend Yield6%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 20:51 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biocon Limited is covered by 42 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Meeta Shetty | Asian Markets Securities Private Limited |
| Harith Ahamed | Avendus Spark |
| Kunal Randeria | Axis Capital Limited |